LENZ THERAPEUTICS, INC. Proceeds from Sale and Maturity of Marketable Securities
LENZ THERAPEUTICS, INC. (LENZ) reported Proceeds from Sale and Maturity of Marketable Securities of $263.43 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-12-31 was $46.45M, a 42.12% decline year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-09-30 was $67.80M, a 24.67% decline year-over-year.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-06-30 was $77.50M.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2023-03-31 was $71.67M.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2023 was $263.43M, a 54.73% increase from fiscal 2022.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $170.25M.
- LENZ THERAPEUTICS, INC. proceeds from sale and maturity of marketable securities for fiscal 2021 was $0.00.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2023-12-31 | $46.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $114.25M derived: sum of 2 quarters · filed 2024-02-27 | $191.75M derived: sum of 3 quarters · filed 2024-02-27 | $263.43M 10-K · filed 2024-02-27 |
| 2023-09-30 | $67.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $145.30M derived: sum of 2 quarters · filed 2023-11-13 | $216.97M 10-Q · filed 2023-11-13 | $297.23M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $77.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $149.18M 10-Q · filed 2023-08-14 | $229.43M derived: sum of 3 quarters · filed 2024-02-27 | $319.43M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | $71.67M 10-Q · filed 2023-05-11 | $151.93M derived: sum of 2 quarters · filed 2024-02-27 | $241.93M derived: sum of 3 quarters · filed 2024-02-27 | $241.93M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $80.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $170.25M derived: sum of 2 quarters · filed 2024-02-27 | $170.25M derived: sum of 3 quarters · filed 2024-02-27 | $170.25M 10-K · filed 2024-02-27 |
| 2022-09-30 | $90.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $90.00M derived: sum of 2 quarters · filed 2023-11-13 | $90.00M 10-Q · filed 2023-11-13 | $90.00M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | $0.00 derived: sum of 3 quarters · filed 2023-08-14 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2023-05-11 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 10-K · filed 2023-03-20 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |